The Regional Market Access Manager (RMAM) is responsible for unimpeded patient access to Provenge within the assigned geographical area. The RMAM will develop and implement strategies that will maximize business opportunities for growth. This position works with regional Payors, state Medicaid plans, medical practice decision makers, CFO’s, CEO’s, pharmacy and medical directors, purchasing departments, key stake holders within state Medicaid departments, insurance companies, community based urology and oncology practices along with academic and community based hospitals, medical centers, clinics, etc. to effectively reduce medical policy restrictions and practice reimbursement barriers. This position will partner with the Dendreon Market Access Director on all payor issues.
Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon is fighting for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer.
Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, we continue to push our research forward so that we may help even more patients fight cancer with personalized immunotherapy.